Therapeutic Yield and Outcomes of a Community Teaching Hospital Code Stroke Protocol

Academic Emergency Medicine

Volumn 11, Issue 4, 2004, Pages 361-370

  Asimos, Andrew W ^a   Norton, H James ^a   Price, Marlow F ^a   Cheek, Wilkie M ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Cerebrovascular accident; Emergency medicine; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; BRAIN HEMORRHAGE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PRODUCT RECOVERY; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; SYMPTOMATOLOGY; TEACHING HOSPITAL;

EID: 1842435214     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1197/j.aem.2003.12.016     Document Type: Article

References (45)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995; 333:1581-7.
2. Grotta J. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA-the best current option for most patients. N Engl J Med. 1997; 337:1310-3.
3. Hoffman JR. Should physicians give tPA to patients with acute ischemic stroke? Against: and just what is the emperor of stroke wearing? West J Med. 2000; 173:149-50.
4. Grotta J, James WE (eds). IV t-PA Interventional Therapy for Acute Stroke Patients: A Debate. The Stroke Interventionalist (ed 2). Englewood, CO: The Stroke Group, 2002, pp 3-10.
5. Wentworth DA, Atkinson RP. Implementation of an acute stroke program decreases hospitalization costs and length of stay. Stroke. 1996; 27:1040-3.
6. Lyden P, Rapp K, Babcock T, et al. Ultra-rapid identification, triage, and enrollment of stroke patients into clinical trials. J Stroke Cerebrovasc Dis. 1994; 4:106-13.
7. Webb DJ, Fayad PB, Wilbur C, Thomas A, Brass LM. Effects of a specialized team on stroke care. The first two years of the Yale Stroke Program. Stroke. 1995; 26:1353-7.
8. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. Stroke. 1997; 28:1530-40.
9. Gomez CR, Malkoff MD, Sauer CM, Tulyapronchote R, Burch CM, Banet GA. Code stroke. An attempt to shorten inhospital therapeutic delays. Stroke. 1994; 25:1920-3.
10. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke. 1998; 29:18-22.
11. Lyden PD, Grotta JC, Levine SR, Marler JR, Frankel MR, Brott TG. Intravenous thrombolysis for acute stroke. Neurology. 1997; 49:14-20.
12. Smith RW, Scott PA, Grant RJ, Chudnofsky CR, Frederiksen SM. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis. Acad Emerg Med. 1999; 6:618-25.
13. Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke. 2000; 31:77-81.
14. Adams HP Jr., Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation. 1996; 94:1167-74.
15. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999; 282:2003-11.
16. Marler JR, Jones PW, Emr M (eds). Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. Bethesda, MD: The National Institute of Neurological Disorders and Stroke. NIH Publication No. 97-4239:157, 1997.
17. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology. 2001; 56:1015-20.
18. Engelstein E, Margulies J, Jeret JS. Lack of t-PA use for acute ischemic stroke in a community hospital: high incidence of exclusion criteria. Am J Emerg Med. 2000; 18:257-60.
19. Zweifler RM, Brody ML, Graves GC, et al. Intravenous t-PA for acute ischemic stroke: therapeutic yield of a stroke code system. Neurology. 1998; 50:501-3.
20. Merino JG, Silver B, Wong E, et al. Extending tissue plasminogen activator use to community and rural stroke patients. Stroke. 2002; 33:141-6.
21. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000; 283:1151-8.
22. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283:1145-50.
23. Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke. 1998; 29:1544-9.
24. Tanne D, Bates VE, Verro P, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology. 1999; 53:424-7.
25. Egan R, Lutsep HL, Clark WM, et al. Open label tissue plasminogen activator for stroke: The Oregon experience. J Stroke Cerebrovasc Dis. 1999; 8:287-90.
26. Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurru C, Biller J. Protocol violations in community-based rtPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke. 2001; 32:12-6.
27. Koennecke HC, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience. Stroke. 2001; 32:1074-8.
28. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol. 2001; 58:2009-13.
29. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke. 2001; 32:1832-40.
30. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998; 29:415-21.
31. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996; 27:373-80.
32. Sacco RL, Boden-Albala B, Gan R, et al. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol. 1998; 147:259-68.
33. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med. 1999; 33:9-14.
34. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000; 55:1649-55.
35. Buchan AM, Barber PA, Newcommon N, et al. Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology. 2000; 54:679-84.
36. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997; 28:957-60.
37. Tanne D, Gorman MJ, Bates VE, et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older the tPA stroke survey experience. Stroke. 2000; 31:370-5.
38. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999; 30:34-9.
39. Cazzato G, Zorzon M, Mase G, Iona LG. Hyperglycemia at ischemic stroke onset as prognostic factor. Ital J Neurol Sci. 1991; 12:283-8.
40. Anonymous. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997; 28:2109-18.
41. Kittaka M, Wang L, Sun N, et al. Brain capillary tissue plasminogen activator in a diabetes stroke model. Stroke. 1996; 27:712-9.
42. Dietrich WD, Alonso O, Busto R. Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke. 1993; 24:111-6.
43. de Courten-Myers GM, Kleinholz M, Wagner KR, Myers RE. Fatal strokes in hyperglycemic cats. Stroke. 1989; 20:1707-15.
44. Wagner KR, Kleinholz M, de Courten-Myers GM, Myers RE. Hyperglycemic versus normoglycemic stroke: topography of brain metabolites, intracellular pH, and infarct size. J Cereb Blood Flow Metab. 1992; 12:213-22.
45. de Courten-Myers GM, Kleinholz M, Holm P, et al. Hemorrhagic infarct conversion in experimental stroke. Ann Emerg Med. 1992; 21:120-6.